Concord Biotech Secures USFDA Approval for Teriflunomide Tablets

Concord Biotech Limited has made a milestone achievement with the United States Food and Drug Administration (USFDA) approving marketing its Teriflunomide tablets. The approvals are for the 7 mg and 14 mg strengths, making Concord Biotech a significant player in managing relapsing forms of multiple sclerosis (MS). Teriflunomide is a pyrimidine synthesis inhibitor that decreases flare-ups and delays the progression of physical symptoms in MS patients.

 

Key Highlights:

This approval reflects Concord Biotech's dedication 85lakhs to driving global healthcare solutions and is another milestone in its path of innovation and excellence. With this success, the company is set to increase its presence in the pharmaceutical sector while making a positive impact on patient outcomes.

 

Source: Pharma Industrial India